Principal Financial Group Inc. Acquires 63,266 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Principal Financial Group Inc. boosted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 18.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,432 shares of the life sciences company's stock after buying an additional 63,266 shares during the period. Principal Financial Group Inc. owned about 0.52% of Integra LifeSciences worth $7,294,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IART. Blue Trust Inc. lifted its holdings in shares of Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock valued at $26,000 after acquiring an additional 444 shares during the period. CWM LLC raised its holdings in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock valued at $37,000 after buying an additional 425 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in shares of Integra LifeSciences in the third quarter valued at about $73,000. Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter valued at about $114,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company's stock valued at $136,000 after buying an additional 1,711 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IART shares. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a report on Monday, October 14th. JMP Securities dropped their price objective on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a report on Tuesday, July 30th. Bank of America dropped their price objective on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Finally, Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of "Hold" and an average target price of $24.00.

Integra LifeSciences Stock Down 0.4 %

Shares of IART traded down $0.10 on Wednesday, hitting $22.78. The company's stock had a trading volume of 159,361 shares, compared to its average volume of 1,091,356. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm's fifty day moving average price is $19.74 and its 200-day moving average price is $24.05. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -254.22, a P/E/G ratio of 0.78 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the prior year, the firm posted $0.76 EPS. The business's revenue was down .4% on a year-over-year basis. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.